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Background: Patients’ knowledge of their atrial fibrillation (AF) and anticoagulation therapy are determinants of the
efficacy of thromboprophylaxis. Nurses may be well placed to provide counselling and education to patients on all
aspects of anticoagulation, including self-management. It is important that nurses are well informed to provide
optimal education to patients. Current practice and knowledge of cardiovascular nurses on AF and anticoagulation
in the Australian and New Zealand (ANZ) context is not well reported.
This study aimed to; 1) Explore the nurse’s role in clinical decision making in anticoagulation in the setting of AF;
2) Describe perceived barriers and enablers to anticoagulation in AF; 3) Investigate practice patterns in the
management of anticoagulation in the ANZ setting; 4) Assess cardiovascular nurses’ knowledge of anticoagulation.
Methods: A paper-based survey on current practices and knowledge of AF and anticoagulation was distributed
during the Australian Cardiovascular Nursing College (ACNC) Annual Scientific Meeting, February 2014. This survey
was also emailed to Cardiovascular Trials Nurses throughout New South Wales, Australia and nursing members of
the Cardiac Society of Australia and New Zealand (CSANZ).
Results: There were 41/73 (56 %) respondents to the paper-based survey. A further 14 surveys were completed
online via nurse members of the CSANZ, and via an investigator developed NSW cardiovascular trials nurse email
distribution list. A total of 55 surveys were completed and included in analyses. Prior education levels on AF, stroke
risk, anticoagulation and health behaviour modification were mixed. The CHA2DS2VASc and HAS-BLED risk stratification
tools were reported to be underused by this group of clinicians. Reported key barriers to anticoagulation included;
fears of patients falling, fears of poor adherence to medication taking and routine monitoring. Patient self-monitoring
and self-management were reported as underutilised. ANZ cardiovascular nurses reported their key role to
be counselling and advising patients on therapy regimens. Anticoagulant-drug interaction knowledge was
generally poor.
Conclusion: This study identified poor knowledge and practice in the areas of AF and anticoagulation. There is scope
for improvement for cardiovascular nurses in ANZ in relation to AF and anticoagulation knowledge and practice.
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Table 1 Final sampling frame response
Distribution method Distribution
sample
Number of
responses
Response
rate
ACNC Conference 73 41 56 %
CSANZ CNC Email list serve 320 2 0.625 %
HF Coordinator Email
distribution list
31 9 29 %
Cardiology Ward 34 3 9 %
Total 458 55 12 %
Legend: ACNC Australian Cardiovascular Nursing College, CSANZ CNC Cardiac
Society of Australia and New Zealand Cardiovascular Nursing Council,
HF Heart Failure
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Atrial fibrillation (AF) is the most common cardiac rhythm
irregularity and increases stroke risk three to five-fold [1].
The population prevalence is estimated at 2.3–3.4 %. The
lifetime risk of AF is approximately 1 in 4 [1]. This inci-
dence increases with age and rises to affect 11 % of the
population over 80 years [2]. This primarily cardiogeriatric
condition is characterised by chaotic electrical activity
in the upper chambers of the heart. Stroke and thrombo-
embolism are major complications of AF. Evidence-based
interventions to reduce stroke risk in AF include anticoa-
gulation and the insertion of a left atrial appendage (LAA)
device, as well as the rhythm control methods such as car-
dioversion and catheter ablation [3]. Oral anticoagulation
is the most common way to reduce stroke risk in indi-
viduals with AF. Whilst the recent advent of new oral
anticoagulants (NOACs) such as the thrombin inhibitor
dabigatran, and factor Xa inhibitors rivaroxaban and
apixaban have held the promise of simplified dosing
without the need for frequent blood testing, concerns
persist of bleeding risk and the lack of any reversal
agent for these agents [3]. To date, warfarin remains
the most commonly used oral anticoagulant, and its use is
inherently burdensome. This burden is often related to
the need for routine monitoring, adaptation of lifestyle
habits and more often than not; complex dosing require-
ments [4]. The quality of overall anticoagulation quality
can be assessed by an individual’s time in therapeutic
range. An individual with AF should aim to maintain their
INR between 2 and 3 [5, 6]. However, many individuals
may find this challenging to achieve due to a variety of
factors. Unstable INRs are likely to be a consequence of
medication, food or lifestyle interactions [7]. Quality
anticoagulation is reliant on patients and caregivers’
knowledge of their chronic condition and anticoagulation
therapy [8]. The often lifetime duration of treatment in-
creases the complex issues of adherence, and emphasises
the need for education refreshment throughout all care
settings. Previous studies have highlighted that clinicians
including physicians, pharmacists, dieticians and nurses
fail to meet adequate knowledge levels to provide accurate
and up-to-date information to patients [9, 10]. A recent
European study drew attention to the need for improve-
ment in cardiovascular nurses’ knowledge and practice on
oral anticoagulant therapy [9]. With an increasing preva-
lence of AF, there is greater need for innovative strategies
to improve patient outcomes. Strategies may include pa-
tient self-testing and self-management. The success of
these strategies are dependent upon appropriate patient
selection [11]. Patients must have good manual dexterity
and cognitive abilities [12]. Further, they must be adept
in managing the device; interpreting, understanding and
taking action based on results. Self-testing and self-
management should not be discounted by clinicians, asa method to improve knowledge, self-efficacy, overall
quality of anticoagulation, and patient outcomes [11].
Nurses account for greater than 50 % of the health
workforce in Australia and often spend the most time
with patients providing clinical care. They are experienced
in counselling, therefore, may be well-placed to provide
patient education on anticoagulation and promote self-
management during regular healthcare interactions.
Study aim
The aim of this study was to:
1) Explore the nurse’s role in clinical decision-making
in anticoagulation in the setting of AF.
2) Describe perceived barriers and enablers to
anticoagulation in AF.
3) Investigate practice patterns in the management of
anticoagulation.
4) Assess cardiovascular nurses’ knowledge of
anticoagulation.
Methods
Design, setting and sample
Data were collected by survey methods. The survey was
conducted at the 8th Annual Scientific Meeting of the
Australian Cardiovascular Nursing College, Gold Coast,
Australia on 22nd Feb 2014. All delegates attending on
this date were invited to participate in the study. Add-
itional responses were sought via an email distribution
list of the Nurses Council of the Cardiac Society of
Australia and New Zealand, and a state-wide cardiovascular
research nurse email distribution list. Additionally, nurses
working in a single site CCU of a metropolitan teaching
hospital were invited to participate. (Refer to Table 1 for
sampling frame response).
Measurements and item generation
A self-report questionnaire, recently used during a Euro-
pean study of cardiovascular nurses was used to assess
variables related to warfarin-drug, warfarin-food inter-
actions and knowledge on novel anticoagulants and
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survey items was approved by the corresponding author.
The original questionnaire was reported as demonstrating
good face validity. Study investigators reviewed the ori-
ginal survey used in Europe, and felt that the variables and
items included were applicable to the ANZ setting, given
the similarities in westernised healthcare systems and
availability of pharmacological agents at the time of the
survey. Additional investigator developed questions were
included; these were developed following consultation
with expert cardiovascular nurses and an extensive review
of the literature. Some questions were adapted from other
surveys that addressed barriers to anticoagulation or elic-
ited the cardiovascular nurse’s role in decision-making
around anticoagulation therapy [13]. The questionnaire
was distributed in English.Data collection
All delegates were provided with a paper-based survey on
their chair during the session and invited by the convenor
to participate. Attendees were asked to place the completed
questionnaires in a designated collection box following the
session. Subsequent to the conference, the same survey was
electronically distributed to nursing members of the
Cardiac Society of Australia and New Zealand and via a
state-wide cardiovascular research nurse email distribution
list. Additionally, nurses working in the hospital CCU
were invited to participate. The hospital site was selected
for inclusion, due to the locality of the site in relation to
the research team’s clinical practice setting. Online survey
methods have previously been used to gain understanding
of practice patterns in the ANZ setting [14]. Therefore,
the research team believed this would yield worthy re-
sponse and enhance findings from the paper-based survey.
To address the potential for selection bias, a poster and
box was placed in the ward setting for clinicians to provide
responses. A notification for completion of the electronic
survey was sent electronically once, and no reminders
were sent. Within the electronic survey information,
participants were advised that this survey was previously
undertaken at the recent ACNC conference, and asked
not to complete if they had already participated.Data management and data analysis
The online survey was conducted using the web-based
SurveyMonkey™ platform (www.surveymonkey.com) and
remained open until 12/05/2014. Paper based surveys were
manually entered into the electronic system; this assisted in
accounting for missing values. The survey ascertained the
basic demographic and education characteristics of nurses
related to highest qualification and length of time working
in cardiovascular nursing. Descriptive analyses were used to
describe the sample and the responses to study variables.Ethical considerations
This study was approved by the St Vincent’s Hospital,
Sydney (Ref: LNR/12/SVH/62) and University of Tech-
nology Sydney (Ref: 2013000181) human research ethics
committees. Approval was provided for both online and
paper-based surveys at the conference. The executive
committee of the Australian Cardiovascular Nursing
College approved survey distribution during the con-
ference event. All conference attendees were informed of
the aims of the study. Informed consent was implied by the
completion of the survey. No identifying information was
collected from the participants to assure confidentiality.
Results
Sample characteristics, demographic information and
experience
A total of 55 responses were included in the analyses.
The table above identifies most responses were from
the ACNC conference, with a response rate of 56 %.
Unfortunately, e-survey distributed by CSANZCNC
once received two responses, notwithstanding the reach of
the email to 320 members. A possible reason for this may
be that some of the members of CSANZCNC are also
members of ACNC, and had attended the conference, and
previously participated in the survey. Most respondents
were female 86 % (n = 47), the majority of respondents
91 % (n = 50) came from the three most populated states
in Australia (New South Wales, Victoria and Queensland).
The remaining respondents were from New Zealand 9 %
(n = 5). The majority worked in a metro area 71 % (n = 39),
and held a Bachelor degree qualification or above 85 %
(n = 47). 33 % (n = 18) identified their current role as
Registered Nurse (RN). Though, the seniority of the clini-
cians was also reflected by the number in expert positions,
36 % (n = 36) identified as Clinical Nurse Consultants or
Nurse Practitioners. Three respondents were not clinicians
and were employed in the higher education & research
sectors. Most 77 % (n = 40) had over 10 years of clinical
experience, and 62 % (n = 34) had worked in cardiovas-
cular nursing specialty practice for more than 10 years.
Baseline demographic information is summarised in
Table 2.
Participation in formal educational programs was re-
ported to be 41–61 % across four associated topics. 48 %
had attended a previous education program about AF,
41 % about stroke risk, 57 % about anticoagulation and
61 % about health behaviour modification. Previous educa-
tion participation is summarised in Table 3.
Adverse outcomes
Fifty percent of respondents had cared for a patient with
AF who had experienced an intracranial haemorrhage
when receiving anticoagulation. And 74 % of respondents
had cared for a patient with AF who had experienced a
Table 2 Characteristics of cardiovascular nurses (n = 55)
Demographic variable n (%)
Female (n = 55) 47 (86)
Highest level of education (n = 55)
• Nursing training
• Bachelor degree
• Graduate certificate
• Master’s degree
• PhD
• Other
5 (9)
15 (27)
11 (20)
16 (29)
5 (9)
3 (6)
Work location (n = 55)
• Metro
• Regional or rural
39 (70)
16 (29)
Country of workplace (n = 55)
• New South Wales
• Australian Capital Territory
• Victoria
• Western Australia
• Northern Territory
• Queensland
• Tasmania
• South Australia
• New Zealand
24 (44)
0
4 (7)
0
0
22 (40)
0
0
5 (9)
Area of specialty practice (n = 55)
• Chronic Heart Failure
• Acute Coronary Syndrome
• Coronary Care Unit
• Cardiac Rehabilitation
• Cardiac Step Down
• Cath Lab
• Research
• Education
• General Medicine
• Other
21 (38)
8 (15)
20 (36)
8 (15)
5 (9)
5 (9)
3 (6)
3 (6)
3 (6)
1 (2)
Current position (n = 55)
• Registered Nurse
• Clinical Nurse Specialist
• Clinical Nurse Educator
• Clinical Nurse Consultant
• Nurse Practitioner
• Other
18 (33)
12 (22)
3 (6)
10 (18)
9 (18)
3 (6)
Years working in clinical practice (n = 52)
• Less than 3
• 4–5
• 6–10
• More than 10
2 (4)
7 (8)
6 (12)
40 (77)
Years working in cardiovascular nursing (n = 55)
• Less than 3
• 4–5
• 6–10
• More than 10
6 (11)
2 (4)
13 (24)
34 (62)
Years working in current department (n = 55)
• Less than 3
• 4–5
• 6–10
• More than 10
13 (24)
13 (24)
14 (26)
15 (27)
Table 2 Characteristics of cardiovascular nurses (n = 55)
(Continued)
Proportion of patients seen aged 65+ (n = 54)
• Less than 25 %
• 26–50 %
• 51–75 %
• 76 % or more
0 (0)
4 (7)
31 (57)
19 (35)
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summarised in Table 4.Nurses role in decision making and anticoagulation
Results of the nurses’ role in decision making are sum-
marised in Table 5. More than half of respondents
(54 %, n = 29) said they were not involved in multidis-
ciplinary team (MDT) discussions when making treat-
ment decisions on anticoagulation management with
patients with AF. Nearly half of respondents agreed
(44 %, n = 24) or strongly agreed (7 %, n = 4) that the
risk of stroke versus the risk of bleeding was clearly
articulated to patients at commencement of anticoa-
gulation for stroke prevention in AF. Most disagreed
(41 %, n = 22) or strongly disagreed (13 %, n = 7) that
they were unsure to advocate for thromboprophylaxis
or not, when involved in team decisions. Most dis-
agreed (50 %, n = 27) or strongly disagreed (6 %, n = 3)
that it was difficult to decide where the benefits of
thromboprophylaxis outweighed the risks of haemor-
rhage. Over half disagreed (57 %, n = 30) that they did
not feel they knew enough about the risks and benefits
of different anticoagulants.
Most respondents (57 %, n = 31) agreed that they took
time to understand their patients views on the risks and
benefits of anticoagulation, and that they (52 %, n = 28)
felt that generally, their patients were well informed
about their risks and benefits of anticoagulation at the
time of commencement. Just under half (n = 26, 48 %)
agreed that their patients received comprehensive edu-
cation about anticoagulation prior to discharge after
hospitalisation. Stroke and bleeding risk stratification
tools were reported to be underutilised by this group of
clinicians. Specifically, only 25 % (n = 13) agreed that
they used a CHADS2 or CHA2DS2-VASc tools, whilst
only 18 % (n = 9) agreed they used the HAS-BLED tool,
despite the fact that both are recommended in internationalTable 3 Previous participation in educational programs
Education program Yes (%)
Atrial fibrillation 26 (48)
Stroke risk 20 (41)
Anticoagulation 29 (57)
Health behaviour modification 31 (61)
Table 4 Clinical Factors
Variable (Clinical Factor) n (%)
Estimated prevalence of AF in CHF
• Less than 25 %
• 25–50 %
• 51–75 %
• 76 % or more
3 (6)
29 (54)
19 (35)
3 (6)
Have cared for a patient with AF who has experienced
an ICH whilst receiving anticoagulation
27 (50 %)
Have cared for a patient with AF who has experienced
a stroke whilst not receiving anticoagulation
39 (74 %)
Actively involved in MDT discussions when making
treatment decisions on anticoagulation management
with patients with AF
25 (46 %)
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52 %) agreed, or strongly agreed that they made use of a
shared decision-making model of care to explain the risks
and benefits of anticoagulation for stroke prevention in AF.
Barriers to anticoagulation
Barriers to anticoagulation are summarised in Table 6.
Barriers to anticoagulation included fears of the patient
falling (75 %, n = 39), fears of poor adherence to: routine
monitoring (75 %, n = 39) and medication taking (71 %,
n = 36). Other barriers included lack of social support (e.g.
patient living alone, or a lack of a caregiver), (41 %, n = 21),
and fears of poor literacy (26 %, n = 13). Factors facilitating
optimal management of thromboprophylaxis were identi-
fied, these are summarised in Tables 7 and 8.Table 5 Clinical decision making in anticoagulation
Statement
The risk of stroke versus the risk of bleeding is clearly articulated to
patients when commencing anticoagulation for stroke prevention in AF
I am unsure whether to advocate for thromboprophylaxis or not when
involved in team decisions
It’s difficult to decide where the benefits of thromboprophylaxis outweigh
the risks of hemorrhage
I feel I do not know enough about the risk and benefits of different
anticoagulants
I take time to understand my patients views on the risks and benefits of
anticoagulation
Generally, my patients are well informed about the risks and benefits of
anticoagulation at time of commencement
My patients receive comprehensive education about anticoagulation
prior to discharge
I use the CHADS2 or CHA2DS2-VASc scores with patients to help risk
stratify stroke risk in clinical practice
I use the HAS-BLED score with patients to help risk stratify bleeding risk in
clinical practice
I use shared decision making with patients to explain the risks and benefits
of anticoagulation for stroke prevention in AFPractice patterns
Results of practice patterns are summarised in Tables 9
and 10. Warfarin remains the most widespread anti-
coagulant used in daily practice for this cohort of clini-
cians (100 %, n = 51). Less extensive use of the novel
agents was reported. Only 16 % (n = 8) of respondents
stated that most patients would be given a choice of
anticoagulant, 82 % (n = 41), stated that ‘some’ patients
may be offered new anticoagulants. 59 % (n = 29) of re-
spondents stated that patients may modify therapy based
on difficulties maintaining INR within therapeutic range
(i.e. 2–3). Patient self-testing and self-management were
not offered by 60 %, (n = 30) of respondents and 28 %,
(n = 14) had never heard of such services. One respond-
ent highlighted a possible rationale for this could be the
limited remuneration and funds for the use of point-of-
care machines. It was also noted by another that phar-
macists had a key role in counselling and education
prior to discharge following a hospitalisation. A number
of respondents highlighted that the role of decision-
making around anticoagulation is usually lead by the
physician, cardiologist or GP and often the nurses and
patients input were minimal.
Cardiovascular nurses’ knowledge on warfarin
interactions
The majority of respondents (n = 34, 69 %) answered
correctly that aspirin enhanced the effect of oral warfarin
anticoagulation therapy. It is of concern that 48 % (n = 23)
of respondents answered incorrectly to interactionsSD D N A SA Rating
Countn (%) n (%) n (%) n (%) n (%)
3 (6) 9 (17) 14 (26) 24 (44) 4 (7) 54
7 (13) 22 (41) 14 (26) 10 (19) 1 (2) 54
3 (7) 27 (50) 10 (19) 14 (26) 0 (0) 54
5 (9) 30 (57) 4 (8) 12 (23) 2 (4) 53
0 (0) 7 (13) 10 (19) 31 (58) 6 (11) 54
3 (6) 8 (15) 11 (20) 28 (52) 4 (7) 54
2 (4) 5 (9) 10 (19) 26 (48) 11 (20) 54
6 (12) 12 (23) 15 (29) 13 (25) 6 (12) 52
11 (22) 13 (26) 16 (31) 9 (18) 2 (4) 51
5 (9) 7 (13) 14 (26) 23 (43) 5 (9) 54
Table 6 Barriers to anticoagulation
Variable (Barrier) n = Y (%) Rate count
Fear of the patient falling 39 (70) 52
Lack of social support 21 (41) 51
(e.g. patient living alone or lack of caregiver)
Fear of poor adherence to medication taking 36 (71) 51
Fear of poor compliance to routine monitoring 39 (75) 52
(e.g. INR checking)
Fears of poor literacy 13 (26) 50
Table 8 Nurse’s general comments to thromoprophyalxis use
General comments about thromboprophylaxis use in patients with AF
“new agent dabigatran easier to manage patients”
“If medical officers have had a patient with a bleed, I find it makes them
more cautious with subsequent patients”
“Some INR levels are very hard to control despite well-educated and compli-
ant patient. Need new ideas i.e. Watchman LAA devices”
“It’s variable and physician choice”
“Until an antidote is developed for the newer anticoagulants we don’t use
them. In some rare cases we do but often last choice”
“Dr’s do all the decision making. Uses CHADS2/ CHA2DS2VASc”
“Quick uptake of NOAC agents but often without evidence (e.g. prosthetic
valves & AF)”
Table 9 Cardiovascular nurses’ practice patterns; use of oral
anticoagulants, involvement in oral anticoagulation therapy
and use of patient INR self-management
Question n (%)
Oral anticoagulants in use in daily practice
• Warfarin (Coumadin)
• Dabigatran (Pradaxa)
• Rivaroxaban (Xareltro)
• Apixaban (Eiliquis)
51 (100)
33 (65)
33 (65)
11 (22)
Will patients be offered a choice of drug?
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interactions with topical salicylates. Whilst ibuprofen
has no effect on oral anticoagulant therapy, it may im-
pact on overall haemostasis and may increase the risk
of gastrointestinal bleeding when used in combination
with oral anticoagulants [15]. Only 23 % (n = 11) of re-
spondents answered correctly that topical salicylates
enhance oral warfarin anticoagulant therapy. Whilst
results of how cardiac agents including propanolol,
cholestyramine and atenolol trend towards the correct
answers (propanolol enhancing, cholestyramine inhibiting
and atenolol having no effect), the rate of respondents
who did not know the interactions of these cardiac agents
on warfarin therapy was 44–67 %. Only 9–22 % answered
the questions on warfarin interactions with gastrointes-
tinal agents correctly. More than two-thirds answered
“don’t know” to the question on sucralfate-warfarin inter-
action. The majority of respondents did not know how
any of the vitamin supplements listed affected warfarin
therapy (range 42–58 % across the 5 supplements). The
questions on the interaction between antibiotics and war-
farin were poorly completed; the majority of respondents
answered “don’t know”. Results on warfarin interactions
are summarised in Table 11.Table 7 Factors facilitating optimal management of
thromboprophylaxis
• Case Management
• Good GP/GP support
• Ease of access to INR checking
• Education
• Counselling assessment
• Discharge planning
• Follow up
• Family support & involvement
• A HAS-BLED and CHADS2 Score
• Open discussion and understanding
of thromboprophylaxis
• Good understanding of risks
and benefits
• Pharmacy education
• Regular adherence and INR
monitoring
• Multi-disciplinary care
• Good communication (including
listening, interpreters, written info)
• Warfarin booklets (written
information)
• Self-management & community
support
• Careful assessment, reassessment
of factors if change
• Monitoring of adherence
• Ensuring type of lifestyle
and therapy is matched with
patients capacity to self-manage
• Nurse-led anticoagulation clinicsCardiovascular nurses’ knowledge on warfarin related
advice
There were eight questions that assessed cardiovascular
nurse’s knowledge on warfarin advice. Responses are
summarised in Table 11. Most questions were answered
correctly with the exception of advice around warfarin
use and pregnancy. 70 % (n = 34) of respondents knew
that patients who are taking warfarin can consume spin-
ach, however that they need to eat the same amount
regularly every week. Over half (55 %, n = 26) correctly
answered that consuming three glasses of wine will cause
an increased in INR. Yet, 21 % (n = 10) of respondents did• No, all patients will be put on warfarin first
• Some patients may be offered new anticoagulation
• Most patients will be given a choice
1 (2)
41 (82)
8 (16)
Will patients on warfarin be able to change to one of the new drugs?
• No, they will need to stay on warfarin
• May change if difficulties keeping INR in therapeutic range
• Any patient can change to one of the new drugs
1 (1)
29 (59)
19 (39)
Do you offer patients INR self-testing or self-management?
• Both self-testing and self-management of INR
• Only self-testing of INR
• Neither self-testing nor self-management
• Never heard about self-testing of self-management of INR
6 (12)
0 (0)
30 (60)
14 (28)
The role of nurses regarding anticoagulants in your country
• Do not have a specific role
• Counsel patients regarding adherence to drug regimen
• Advice patients on dosing warfarin based on INR results
• Teach about drugs, how to take them and side effects
11 (21)
34 (65)
8 (15)
33 (64)
INR international normalized ratio
Table 10 Cardiovascular nurses’ knowledge on warfarin-drug interactions
Question n (%) n (%) n (%) n (%)
Enhance Inhibit No effect Don’t know Rating Count
How to these anti-inflammatory agents affect oral warfarin anticoagulant therapy?
• Aspirin
• Ibuprofen
• Topical salicylates
34 (69)
23 (48)
11 (23)
2 (4)
8 (17)
3 (6)
9 (18)
9 (18)
11 (23)
4 (8)
8 (17)
23 (48)
49
48
48
How do these cardiac agents affect oral warfarin anticoagulant therapy?
• Propanolol
• Cholestyramine
• Atenolol
7 (15)
0 (0)
5 (11)
2 (4)
10 (21)
1 (2)
15 (32)
6 (13)
20 (44)
23 (49)
32 (67)
20 (44)
47
48
46
How do these gastrointestinal agents affect warfarin anticoagulant therapy?
• Antiacids
• Cimetidine
• Metamucol
• Sucralfate
0 (0)
4 (9)
1 (2)
0 (0)
23 (49)
11 (24)
10 (22)
10 (22)
7 (15)
4 (9)
5 (11)
5 (11)
17 (36)
27 (59)
30 (65)
30 (67)
47
46
46
45
How do these vitamin supplement (s) affect oral anticoagulant therapy?
• Multivitamin
• Multivitamin and minerals
• Antioxidant formula
• 1200 IU vitamin E
• 1000 mg vitamin C
2 (4)
2 (4)
7 (16)
18 (39)
4 (9)
9 (20)
9 (20)
3 (7)
5 (11)
3 (7)
15 (33)
15 (33)
9 (21)
3 (7)
12 (27)
19 (42)
19 (42)
25 (57)
20 (44)
26 (58)
45
45
44
46
45
Most antibiotics affect warfarin therapy by the process of:
• Potentiation
• Inhibition
• Both
• Neither (other process)
7 (23)
5 (17)
6 (19)
1 (4)
0 (0)
0 (0)
1 (4)
2 (8)
24 (78)
25 (84)
25 (78)
23 (89)
31
30
32
26
Correct answers are shown in bold
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diovascular nurses knew that the best time of day to take
warfarin was the evening, and 90 % (n = 45) were aware
that patients with a stable INR should have it checked
every 4 weeks. Only 58 % (n = 29) of nurses would have
given correct advice to patients on the action to take if
a patient remembered missing a last dose. Over three
quarters (76 %, n = 38) of respondents correctly an-
swered that once warfarin is ceased, it takes 5 days to
be cleared from the patient’s body. Most (84 %, n = 43)
nurses correctly identified that the length of time a pa-
tient is expected to be taking warfarin is patient centric,
and dependant on individual needs. Only 12 % (n = 6)
of respondents correctly answered that women who are
pregnant can safely take warfarin during the second
and third trimester. Less than half, 48 % (n = 24) of re-
spondents incorrectly answered this question, wrongly
identifying that pregnant women should not take warfarin,
which is concerning around the correct information
provision to this patient population.
Discussion
This study demonstrates that cardiovascular nurses in
Australia and New Zealand have insufficient knowledge
on oral anticoagulant therapy, warfarin-diet, and warfarin-
medication interactions. Our findings are consistent with
recent international research [7, 9]. The less extensivereported use of novel agents may be due to their gradual
introduction to the Pharmaceutical Benefit Scheme (PBS).
The PBS is the national pharmaceutical rebate scheme
providing medicines at a government-subsidised price. It
is of concern that such a small percentage stated that most
patients would be given a choice of anticoagulant. There
remains considerable scope for improvement in this area
of shared decision-making.
The lack of knowledge of warfarin-medication inter-
actions is alarming. It is of concern at the lack of know-
ledge on warfarin related advice, particularly pertaining
to pregnancy and how alcohol affects INR. Our findings
represent a typically older and more experienced car-
diovascular nursing population, working in specialised
positions with advanced qualifications. And as such, are
likely to be more knowledgeable on anticoagulation
than other nurses. Given the overall poor results, it is
feared that knowledge is likely to be even poorer in the
broader nursing population.
Practice patterns
The cardiovascular nurses surveyed stated that warfarin
remains the most widespread oral anticoagulant for stroke
prevention in AF, whilst NOACs are reported to have lesser
usage. It is concerning that only 16 % of respondents stated
that most patients would be given a choice. It appears that
there is scope for improvement in the practice of shared
Table 11 Cardiovascular nurses knowledge on how to advise
patients on warfarin
Question n (%)
While on warfarin the patient:
• Should not eat spinach
• Can eat spinach once a month
• Can eat as much spinach as he
likes whenever he likes
• Can eat spinach but needs to eat
the same amount every week
• Don’t know
• Skipped question
9 (18)
1 (2)
2 (4)
34 (69)
3 (6)
6
While out with friends for dinner, your patient has just finished his third
glass of wine. This amount of alcohol consumed in a single evening will:
• Cause a decrease in INR
• Cause an increase in INR
• Does not affect warfarin in any way
• Make the patient sick when taking
warfarin medication
• Don’t know
• Skipped question
7 (15)
26 (55)
3 (6)
1 (2)
10 (21)
8
The best time of day to take warfarin is:
• At lunchtime
• In the evening
• In the morning before breakfast
• Any time of the day when you remember
• Don’t know
• Skipped question
0 (0)
44 (88)
2 (4)
3 (6)
1 (2)
5
Once the patient has reached a stable warfarin dose, a PT/INR blood
test:
• Should be checked once a year
• Should be checked once every 3 months
• Should be checked at least once every 4 weeks
• Does not need to be checked once on a
stable warfarin does
• Don’t know
• Skipped question
0 (0)
5 (10)
45 (90)
0 (0)
0 (0)
5
A patient just remembered that he forgot to take his warfarin
medication dose last night. He/She should:
• Skip in the dose of warfarin he/she missed
• Take the missed warfarin dose right now
• Wait and take two doses right now
• Take one-half of the missed dose of
warfarin right now
• Don’t know
• Skipped question
29 (58)
8 (16)
0 (0)
8 (16)
5 (10)
5
Once the patient’s warfarin is stopped, how long does it take to get the
medication out of his/ her system?
• 5 h
• 5 days
• 5 weeks
• 5 months
• Don’t know
• Skipped question
1 (2)
38 (76)
2 (4)
0 (0)
9 (18)
5
After starting warfarin, how long (in months/years) would you expect
the patient to be taking warfarin?
• 1 year
• 1 month
• It depends on each person’s needs
• If you start warfarin you will have to be
on the medication for the rest of your life
• Don’t know
• Skipped question
0 (0)
0 (0)
43 (84)
9 (18)
0 (0)
4
Table 11 Cardiovascular nurses knowledge on how to advise
patients on warfarin (Continued)
Women who are pregnant:
• Should not take warfarin
• Can safely take warfarin during the second
and third trimester
• Can take warfarin but only need to take
it every others day
• Would not need to take warfarin, since being
pregnant prevents them from getting blood clots
• Don’t know
• Skipped question
24 (48)
6 (12)
0 (0)
0 (0)
20 (40)
5
Correct answers are shown in bold
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that nurses maintain an active role in the decision-making
processes and act as an advocate for patients and caregivers.
This may be particularly problematic when patients are
presented with complex risk calculators and benefit statis-
tics of various treatments. Patient self-testing and self-
management strategies have been not yet been embraced as
innovative practices that support able patients. Barriers to
patient self-management and self-testing include frailty,
poor manual dexterity and cognitive dysfunction [12];
however these practices should not be discounted by
clinicians. Additionally, a poor rebate for self-testing
devices may also impede uptake in Australia and New
Zealand. The nurse’s role in education and counselling
on anticoagulation was highlighted. Some respondents
expressed that they often delegate this to the pharma-
cist for education. This practice appears commonplace,
and is worrisome. A respondent expressed “most times,
little education is given”. This has immense implication
for the quality of thromboprophylaxis.
Knowledge
Cardiovascular nurses must ensure that they are up-to-
date with current evidence-based information on AF
and anticoagulation therapy to inform the education
and care they provide to patients. Incorrect and inaccurate
knowledge on drug-drug, drug-food interactions and
monitoring requirements was prevalent among the re-
spondents to our survey. This may lead to inappropriate
patient counselling and education. This would adversely
impact patient outcomes. It is therefore vital that cardiovas-
cular nurses are knowledgeable and keep abreast with new
information related to AF and anticoagulation practices.
Support for self-testing and self-management practices
must be preferred over teaching alone. Nurses are best-
placed to provide ongoing counselling throughout the
spectrum of care; from hospitalisation to discharge and
within primary care settings. However, the quality of
this counselling is dependent on a strong contemporary
knowledge base. Cardiovascular nurses must refrain from
simple task delegation of anticoagulation education to
Implications for Clinical Practice
• ANZ cardiovascular nurses need to improve their knowledge on oral
anticoagulant therapy.
• Lack of clinician knowledge may lead to inaccurate patient advice
and impact adherence to therapy.
• Including a comprehensive education program pre-discharge may
help to improve the quality and safety of anticoagulation
• Cardiovascular nurses need to be more actively involved in
anticoagulation decision making in the clinical setting.
• Due to the duration of therapy for this chronic condition, there is
need for education refreshment and re-assessment of patients and
clinicians knowledge, across all care settings.
• There is need to explore the scope for professional organisations to
credential nurses on AF and anticoagulation.
Ferguson et al. BMC Medical Education  (2016) 16:9 Page 9 of 10pharmacists or other clinicians, it is important to adopt
a combined and comprehensive approach. This may assist
in optimising therapy, improving issues of adherence and
ultimately patient outcomes. Clinicians must engage
further with this topic to ensure safe care. Results from
this study highlight the need for cardiovascular nurses to
maintain a contemporary knowledge base. The Australian
Health Practitioner Regulation Agency (AHPRA) man-
dates that all registered nurses must participate in at least
20 h of continuing nursing professional development per
year that is relevant to the context of practice [16]. Educa-
tion modules specific to AF and anticoagulation, including
stroke and bleeding risk and lifestyle modification may be
of assistance in maintaining minimum standards for
continuing professional development for cardiovascular
nurses.
Limitations
This study has some limitations. Firstly, whilst the response
rate of 58 % to the paper-based survey distributed during
the conference is encouraging, the generalizability of these
findings is difficult. These findings represent a typically
older and more experienced cardiovascular nursing
population, working in specialised positions with higher
qualifications. Therefore this may not be representative
of the general Australian and New Zealand cardiovas-
cular nursing population whom provide bedside patient
education on anticoagulation. Secondly, the majority of
respondents (80 %) were attending a cardiovascular nursing
conference, for many of the workforce this remains a privil-
ege to secure funding and time to attend such professional
development events. The seniority of respondents may re-
flect the demographic that normally attends conferences,
hold a professional society membership or has access
to a workplace email account. Again, this limits the
generalizability of findings.
Conclusions
The results of our study demonstrate that of the cardio-
vascular nurses surveyed in Australia and New Zealand
most had inadequate knowledge on oral anticoagulant
therapy. There is need for improvement, to ensure qual-
ity of care for patients with AF receiving anticoagulation.
Cardiovascular nurses need to be able to provide accurate,
robust and timely advice to patients to topics including
lifestyle, medication and food interactions to anticoagula-
tion. A lack of knowledge on these topics may contribute
to inappropriate counselling and education. Further, the
communication of inaccurate information may implicitly
reinforce myths and misconceptions around anticoagula-
tion. The education of patients on anticoagulation is not a
role of a single health professional. A team approach must
be taken and nurses have a key role in providing answers
to questions and sound clinical advice across all caresettings. Future research should address modes of delivery
of AF and anticoagulation education for clinicians, individ-
uals and their caregivers.Competing interests
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